Evolva selected to acquire certain Fluxome assets

21. Nov 2012

Reinach, Switzerland, 21 November 2012 – Evolva Holding SA (SIX: EVE) today announces it has entered an agreement to acquire certain assets owned by Fluxome Sciences A/S, a Danish private company that is in reconstruction. The agreement is subject to creditor and court approval, which is anticipated to occur in the next two weeks. Further information will be provided if approval is obtained. The transaction is not expected to change Evolva’s 2012 financial projections.

– Ends –

Download Press Release in English

Download Press Release in German

About Evolva

Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. For more information see www.evolva.com.

 

Contact Details
Evolva

Neil Goldsmith
CEO
[email protected]
+ 41 61 485 2005
Jakob Dynnes Hansen
CFO
[email protected]
+ 41 61 485 2034
Paul Verbraeken
IR
[email protected]
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

cancel

Sign up to receive our
Press Releases!

Sign up